Design Therapeutics announced its Q1 2026 financial results, reporting a net loss of $17.6 million and holding $222.8 million in cash and securities to fund operations through 2029. The company is progressing clinical trials for its GeneTAC® platform, including the RESTORE-FA trial for Friedreich ataxia, with data on frataxin levels expected in late 2026. Additional trials for Fuchs Endothelial Corneal Dystrophy and Myotonic Dystrophy Type-1 are underway or planned, alongside preclinical work for Huntington’s disease. The appointment of Dr. David Shapiro to the board strengthens clinical and regulatory expertise as the company advances its pipeline.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
Crypto investigator ZachXBT criticized all current hardware wallets as insecure and unreliable for signing transactions or storing significant funds. He highlighted Ledger as particularly problematic due to frequent updates that disrupt basic functio...
DMG Blockchain Solutions announced two strategic investments: one in MeetAmi Innovations, a Canadian fintech offering digital asset wealth management platforms, and another in Atomic47 Labs, an AI company focused on secure, sovereign AI infrastructur...
